Oxford Biomedica.

While it is true that buy notes fom Beeson Gregory are generally not worth the paper they are printed on, OXB remains an interesting company, I would be suprised if the price did not move significantly ahead on a two year perspective. Enthusiasm for Biotechs tends to move in cycles, with investors and analysts generally as cluess at the low points of the cycle as they are at the highpoints, sentiment and a sexy sounding leading edge agenda are much more important than real prospects, OXB would appear to have both though, at least to some degree.